For adults with acute myeloid leukemia (AML), pretransplant NPM1 measurable residual disease (MRD) is prognostic for relapse, according to a study recently published in Bone Marrow Transplantation.
Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood ...
James Dentzer, President and CEO, stated that "we continue to make steady progress in our TakeAim Lymphoma study in primary CNS lymphoma, one of the most rare and most difficult to treat of the NHL ...
Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AMLHOUSTON, ...
Cuba’s government granted NBC News rare access inside the Institute of Hematology and Immunology, a research facility in the ...
Ashley Park discussed her childhood cancer journey at SXSW in Austin March 14.
Soheil Meshinchi, MD, PhD, a world leader in developing novel approaches to treating acute myeloid leukemia (AML), has been ...
Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat ...
Henry Repeating Arms has produced a limited-edition series of Golden Boy Silver rifles to help fund treatment for wildland ...
Pillar Biosciences today announced the launch of the oncoReveal ® Rapid AML Panel, a focused research-use-only (RUO) DNA next-generation sequencing (NGS) panel designed to help laboratories generate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results